Project Grant R33HL175682
Award Date
8/21/24
Completion Date
6/30/26
Dollars Obligated
$464K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research on a peptide derived from collagen XVIII that has demonstrated anti-fibrotic effects in preclinical models of lung fibrosis. The goal is to assess the therapeutic potential of this peptide in a murine model of lung fibrosis, identify the minimal effective dose and optimal dosing frequency, and conduct...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $805,845 to the Proteogenomics Research Institute for Systems Medicine to develop and test a novel lung precision drug delivery system (LPDDS) targeting lung myofibroblasts to treat lung fibrosis. The goal is to create "dual precision" bispecific therapeutics that can actively transport anti-fibrotic agents directly...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $306,748 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Mechanobiologix LLC. The award, with a performance period from September 2024 to September 2025, supports the development of a stiffness-based drug discovery platform to evaluate therapeutic and preventive capabilities of anti-fibrotic drugs for Idiopathic Pulmonary Fibrosis (IPF). The...
This $774,585 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the mechanisms underlying the emergence and functional role of inflammatory fibroblasts in pulmonary fibrosis. Key research activities include: Comparing the timing, persistence, and fate of inflammatory fibroblasts in mouse models of pulmonary fibrosis (bleomycin, silica) versus an...
The federal Project Grant award R01HL172490 for $693,306.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to examine the role of fatty acid oxidation and the mitochondrial protein CPT1A in regulating alveolar epithelial cell differentiation and resilience against lung fibrosis. The research aims to determine how CPT1A-mediated fatty acid oxidation in alveolar type 2 (AT2) cells...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $542,402 grant, awarded on April 1, 2025, supports a collaborative research project between Henry Ford Health and Michigan State University Health Sciences to identify small molecule compounds that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded Novomedix LLC a $306,872 Project Grant to develop and commercialize a novel, safer, and more effective therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrosis conditions. Novomedix has developed a series of small molecule compounds that inhibit myofibroblast activation and differentiation, potentially reversing fibrotic...
This $1,660,873 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of the enzyme 15-PGDH in cardiac fibrosis and heart failure. The research aims to investigate how inhibiting 15-PGDH can suppress the activation of cardiac fibroblasts and prevent or reverse pathological cardiac fibrosis, a key contributor to diastolic dysfunction and heart failure with preserved ejection...
This $1,546,880 five-year federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the regulation of myofibroblast gene expression in idiopathic pulmonary fibrosis (IPF). The research aims to determine the "regulatory architecture" of open chromatin regions in IPF myofibroblasts, examine how expression of E-box transcription factors like TWIST1 regulate...